BXRX · Baudax Bio, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Revenue | $1.27M | $1.08M | $493.0K | - |
| Cost of Revenue | $7.01M | $2.44M | $1.73M | - |
| Gross Profit | ($5.74M) | ($1.36M) | ($1.24M) | - |
| R&D | $3.89M | $3.13M | $9.09M | $35.58M |
| SG&A | $24.12M | $45.31M | $43.34M | $29.45M |
| Total Operating Expenses | $58.08M | $20.09M | $75.28M | $73.53M |
| D&A | $165.0K | $240.0K | $408.0K | $480.0K |
| Operating Income | ($56.81M) | ($19.01M) | ($74.79M) | ($73.53M) |
| Interest Expense | - | $2.30M | $1.36M | - |
| Income Tax | $0 | $0 | $0 | $0 |
| Net Income | ($58.80M) | ($19.77M) | ($76.10M) | ($73.67M) |
| EPS - Basic | ($361.16) | - | - | - |
| EPS - Diluted | ($361.16) | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Cash & Equivalents | $5.26M | $15.89M | $30.34M | $17.74M |
| Accounts Receivable | $335.0K | $542.0K | $51.0K | $273.0K |
| Inventory | $0 | $5.00M | $2.98M | - |
| Accounts Payable | $3.93M | $1.47M | $3.65M | $271.0K |
| Current Assets | $6.35M | $23.49M | $36.72M | $20.14M |
| Total Assets | $10.03M | $53.28M | $68.73M | $54.21M |
| Current Liabilities | $21.46M | $15.65M | $18.13M | $7.71M |
| Long-term Debt | $1.52M | $6.31M | $8.47M | - |
| Total Liabilities | $34.27M | $40.05M | $83.53M | $70.93M |
| Stockholders' Equity | ($24.24M) | $13.23M | ($14.80M) | ($68.35M) |
| Retained Earnings | ($190.90M) | ($132.09M) | ($112.32M) | ($36.22M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Operating Cash Flow | ($27.79M) | ($49.27M) | ($44.06M) | ($59.75M) |
| Investing Cash Flow | ($20.0K) | ($194.0K) | ($639.0K) | ($3.45M) |
| Financing Cash Flow | $17.18M | $35.01M | $57.30M | $63.20M |
| CapEx | $20.0K | $203.0K | $639.0K | $3.37M |
| Free Cash Flow | ($27.81M) | ($49.47M) | ($44.70M) | ($63.12M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|
| Profitability | ||||
| Gross margin | -452.3% | -126.4% | -251.3% | - |
| Operating margin | -4477.0% | -1759.8% | -15169.6% | - |
| EBITDA margin | -4464.0% | -1737.6% | -15086.8% | - |
| Net margin | -4633.2% | -1830.5% | -15436.1% | - |
| Free cash flow margin | -2191.7% | -4580.8% | -9066.3% | - |
| FCF / Net income | 0.47 | 2.50 | 0.59 | 0.86 |
| R&D / Revenue | 306.3% | 289.4% | 1843.2% | - |
| SG&A / Revenue | 1900.6% | 4195.4% | 8790.1% | - |
| Effective tax rate | - | - | - | - |
| Return on assets | -586.1% | -37.1% | -110.7% | -135.9% |
| Return on equity | 242.5% | -149.5% | 514.2% | 107.8% |
| Return on invested capital | - | -76.9% | - | - |
| Liquidity | ||||
| Current ratio | 0.30 | 1.50 | 2.03 | 2.61 |
| Quick ratio | 0.30 | 1.18 | 1.86 | 2.61 |
| Cash ratio | 0.25 | 1.02 | 1.67 | 2.30 |
| Leverage | ||||
| Debt / Equity | -0.06 | 0.48 | -0.57 | - |
| Debt / Assets | 0.15 | 0.12 | 0.12 | - |
| Debt / EBITDA | - | - | - | - |
| Interest coverage | - | -8.3x | -55.0x | - |
| Equity multiplier | -0.41 | 4.03 | -4.64 | -0.79 |
| Liabilities / Assets | 3.42 | 0.75 | 1.22 | 1.31 |
| Efficiency | ||||
| Asset turnover | 0.13 | 0.02 | 0.01 | - |
| Inventory turnover | - | 0.49 | 0.58 | - |
| Days sales outstanding | 96d | 183d | 38d | - |
| Days inventory outstanding | 0d | 747d | 628d | - |
| Days payable outstanding | 205d | 219d | 770d | - |
| Cash conversion cycle | -108d | 711d | -104d | - |
| Valuation | ||||
| P / E | - | - | - | - |
| P / B | - | - | - | - |
| P / S | - | - | - | - |
| EV / EBITDA | - | - | - | - |
| Growth | ||||
| Revenue growth (YoY) | 17.5% | 119.1% | - | - |
| Revenue CAGR (3y) | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - |
| Gross profit growth (YoY) | -320.5% | -10.2% | - | - |
| Operating income growth (YoY) | -198.9% | 74.6% | -1.7% | - |
| Net income growth (YoY) | -197.4% | 74.0% | -3.3% | - |
| EPS growth (YoY) | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - |
| FCF growth (YoY) | 43.8% | -10.7% | 29.2% | - |
| FCF CAGR (5y) | - | - | - | - |
| Book value growth (YoY) | - | - | 78.3% | - |
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-34.96
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Baudax Bio against the 5 most active filers in the same SIC group.